Sema4 and CM Life Sciences filed a preliminary proxy outlining their proposed business combination. A meeting date has not be set for a shareholder vote on the deal.
Sema4 is health intelligence company leveraging AI and machine learning to derive data-driven insights on patient care and treatment.
Announced in February, financing for the $793 million deal includes a fully committed PIPE of $350 million from growth and life science investors including Casdin Capital, Corvex Management, Fidelity Management & Research Company, Counterpoint Global (Morgan Stanley), Perceptive Advisors, SB Management, a subsidiary of SoftBank Group Corp, funds and accounts advised by T. Rowe Price Associates Inc and Viking Global Investors, and existing investors including fund and accounts managed by Blackrock and Deerfield Management. Read more.
